Lupin Limited is a geographically diversified pharmaceutical formulator that makes its money from four engines: a US generics business that earned USD 1,318 million in FY26 (up 40% YoY), India branded prescription formulations worth INR 8,114 crores in FY26 growing 7.1%, Other Developed Markets (Europe, Canada, Australia) at INR 3,244 crores, and Emerging Markets at INR 3,483 crores growing 35.2%. The quality signal sits in the margin line: FY26 EBITDA margin reached 29.7%, up 590 bps YoY and well above the 27-28% guided range, with gross margin at 73.3% versus 69.2% a year earlier. For a generics-heavy manufacturer, sustained margins near 30% are exceptional and reflect a mix shift toward complex products rather than commodity volume. The competitive structure supports this: in Tolvaptan Lupin was the only generic on the market with under 40% molecule penetration, in Mirabegron it held roughly 40% of generic share alongside one peer, and in India it competes against a fragmented branded-generics field where it grew core prescriptions at 1.1x IPM in FY26 and 1.1x again in Q1FY27.
The economics persist because the company has deliberately moved up the difficulty curve. Respiratory products like Tiotropium (share settled around 38%) and Albuterol require device-and-formulation capability few can replicate, the Nanomi long-acting injectable platform produced Risperdal Consta under CGT exclusivity where demand exceeds supply, and Ranibizumab is differentiated with both pre-filled syringe and vial while most competitors offer vial only. Biosimilars are structurally concentrated: management notes only a handful of scaled players globally across India, Europe and Korea, and Lupin claims to be the only integrated biosimilar player with an India cost advantage owning both API and finished product. First-to-file positions such as Ivacaftor, Diazepam nasal spray and Epinephrine nasal spray carry regulatory barriers measured in years. The offsetting truth is that plain-vanilla US generics remain price-eroded, with Albuterol share already slipping from 19-20% to 16%, so the moat is real only in the complex layer now being built.
The next 18-24 months are a two-act story. Act one is FY27 as a guided transition year: high single-digit revenue growth, EBITDA margin normalizing to around 25% (CFO range 24-25%) from 29.7%, US revenue dipping to USD 1.1-1.2 billion as Mirabegron competition hits fully from Q2 and Tolvaptan adds Apotex and Teva with a possible fourth entrant from September 2026, pushing US quarterly revenue down to USD 250-280 million. Act two begins from FY28: Pegfilgrastim launches in H2 FY27 with meaningful contribution, Apixaban 505(b)(2) targets a September FDA goal date with commercial quantities from January 2027 and a summer launch carrying a 10-12 month exclusivity window at potentially Mirabegron/Tolvaptan scale, Ranibizumab lands later in FY27 with material FY28 impact, and FY28 brings Dulera, Diazepam and Epinephrine nasal sprays, iron sucrose, Saxenda and exclusive first-to-file Ivacaftor. By mid-FY28 the picture is a US business back on a growth trajectory off the FY27 base, biosimilars ramping toward a couple hundred million dollars over three years from about USD 50 million today, VISUfarma consolidated from Q1 FY27 and tracking past USD 100 million within 2-3 years, Europe compounding at 10-20%, and India chronic mix moving from 66% toward 70% with oral Semaglutide launching in H2 FY27.
Management's walk matches its talk unusually well. In August 2025 it guided FY26 EBITDA margin at 24-25%; by February 2026 it raised this to 27-28%, and the year printed 29.7%, beating even the raised range by nearly 200 bps, with Q3FY26 alone at 31.1%. The promised milestones have landed on schedule: Pegfilgrastim approval and Valorum partnership were committed before end-Q3FY26 and delivered, Somerset received VAI-status EIR during Q1FY27, VISUfarma closed and consolidated from Q1 FY27 as promised, and Brazil's Dapagliflozin-driven 117% YoY local-currency growth followed the stated Emerging Markets playbook. Guidance discipline continues into FY27: the May 2026 call set 24-25% margins and the August 2026 call reiterated around 25% despite a record Q1 above 30%, explicitly banking conservatism for known competition. Capital allocation is conservative and accretive: net cash of INR 4,636 crores at March 2026 fell to INR 2,831 crores at June 2026 after funding VISUfarma without dilution, working capital sits at 90 days versus 110 days a year ago, and ROCE improved to 29.5% from 28.4%.
The quantified path: if FY27 delivers roughly 25% EBITDA on high single-digit growth and the FY28 launch wave (Apixaban 505(b)(2), full-year Pegfilgrastim, Ranibizumab, Dulera, nasal sprays) restores US growth, earnings should trough in FY27 and re-accelerate through FY28 with a richer complex-product mix supporting margins above the guided level, mirroring the FY26 pattern where guidance was beaten. What must be true: the Apixaban approval arrives near the September goal date, Pegfilgrastim ramps per partner forecasts, Pithampur Unit II remediation closes without escalation, and freight or input inflation does not consume more than the cushioned Q1 gross margin of 74.6% suggests. The kill shot is the US quarterly run-rate: if USD 250-280 million quarters stretch beyond the next couple of quarters because Tolvaptan share erodes faster than the expected specialty-pharmacy tail, or the fourth entrant arrives early, the FY28 recovery math breaks and the thesis degrades from compounder to a lower-margin generics cycle. Watch the Q2 and Q3 FY27 US prints and the Apixaban approval decision as the falsifiers.
companyname: Lupin Limited ticker: LUPIN sector: Pharmaceuticals (Generics, Complex Generics, Biosimilars, Specialty) Lupin is a global pharmaceutical company founded in 1968 by Dr. Desh Bandhu Gupta, headquartered in Mumbai. In FY26 it reported consolidated revenue from operations of INR 279,580 million, EBITDA of INR 92,405 million (33.6% margin), and profit after tax of INR 53,555 million, with ROCE of 28.4%. It operates 15 manufacturing sites, 7 R&D centers, employs more than 26,000 people,...
Read the full report →new product segment, geographic expansion, acquisition inorganic
FY27 revenue growth guided at high-single digits with EBITDA margins around 25%
Guidance upgradedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Lupin Limited and 4,900+ companies.
5-day free pass. No card required.